Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-22
2008-07-22
Kim, Jennifer (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S811000, C514S812000
Reexamination Certificate
active
07402591
ABSTRACT:
An analgesic composition in parenteral unit dosage form or in a unit dosage form suitable for delivery via the mucosa comprising an amount of buprenorphine which is less than the clinical dose required to achieve pain relief and an amount of naloxone such that the ratio by weight of buprenorphine to naloxone is in the range of from 12.5:1 to 27.5:1, or an amount of naltrexone or nalmefene such that the ratio by weight of buprenorphine to naltrexone or nalmefene is in the range of from 12.5:1 to 22.5:1. The analgesic action of the buprenorphine is potentiated by the low dose of naloxone, naltrexone or nalmefene.
REFERENCES:
patent: 5512578 (1996-04-01), Crain et al.
patent: 2 150 832 (1985-07-01), None
patent: 2 167 663 (1986-06-01), None
patent: WO 96/02251 (1996-02-01), None
Thomas Eissenberg et al., “Buprenorphine's Physical Dependence Potential: Antagonist-Precipitated Withdrawal in Humans 1”, The Journal of Pharmacology and Experimental Therapeutics, The American Society for Pharmacology and Experimental Therapeutics, JPET vol. 276: pp. 449-459, 1996.
Chapleo Christopher Bourne
McCormack Keith
Varey Nicolas Calvert
Fish & Richardson P.C.
Kim Jennifer
Reckitt Benckiser Healthcare (UK) Limited
LandOfFree
Analgesic compositions containing buprenorphine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Analgesic compositions containing buprenorphine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic compositions containing buprenorphine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2768914